ClinicalTrials.gg
CompletedNCT07069725PECHORAUpdated Jul 27, 2026

The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

A Phase 1 interventional study of AZD2389 and PET scan and radioligand in Liver Fibrosis and Hepatic Cirrhosis, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Liver Cirrhosis by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Liver Cirrhosis · AstraZeneca.

Enrollment
11th of 11
8 · median 40
Started
2025
with 3 others
Phase 1
5 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Liver Cirrhosis by AstraZeneca, this one is the 11th largest by enrollment, is one of 4 that started in 2025, is one of 5 in phase 1, and was the 10th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

1 of the 11 studies in Liver Cirrhosis by AstraZeneca is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Liver Cirrhosis by AstraZeneca, or all of them as a file.
02

Study summary

This is a phase 1, open-label, PET trial. The study is designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.

Read the detailed description

This is a phase 1, open-label, PET trial in male and female patients with advanced liver fibrosis. The trial will consist of up to 3 sequential panels: Part A (Pilot panel), Part B (Main panel - 3 dose levels of AZD2389, 2 participants per dose level.), and Part C (optional panel). The design of the trial is adaptive and adjustments in time points and/or number of assessments and samples can be made during the course of the trial.

03

Conditions studied

  • Liver Fibrosis
  • Hepatic Cirrhosis

Browse trials for

Keywords

  • Liver Fibrosis
  • Hepatic Cirrhosis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female (of non-) participant aged ≥ 20 years and willing and able to give written for participation in the trial.
  2. History confirming compensated liver cirrhosis.
  3. Females must have a negative pregnancy test.
  4. Barrier use by males.

Key Exclusion Criteria:

  1. A condition that would interfere with evaluation of the trial intervention, put the participant at risk, influence the participant's ability to participate or affect the interpretation of the results of the trial.
  2. Any illness, medical or major surgical procedure or trauma prior randomization.
  3. , and/or infection.
  4. Significant elevations in liver blood test, MELD score >12 and \<100 x109/L g).
  5. ) \< 60 ml/min/1.73m2.
  6. History of decompensated liver cirrhosis.
  7. Any participants with an aetiology of liver cirrhosis where the Investigator considers that PET signal uptake may be impacted.
  8. History of bleeding disorders and major bleeding risk.
  9. History of severe dermatological disorders or wound healing.
  10. Positive screening result for drugs of abuse or alcohol.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Other
    Part A

    In Part A, eligible participants (screening Visit 1) will return to the trial site for pre-assessments, confirmation of eligibility criteria, blood sampling for FAP concentration analysis (at the trial site), and the first PET examination (screening Visit 2). The participants will perform the PET examination at the PET Centre using the radioligand \[68Ga\]Ga-FAPI-46. Depending on the results of the initial PET examination, participants of Part A may be invited to continue the trial in Part B. In such a case they will participate in a total of 3 PET examinations, not exceeding predefined radiation exposure limits. If they do not participate further, they will complete the trial with a follow-up visit (Visit 3, telephone call) 7 days (±2 days) after the PET examination.

    Diagnostic Test: PET scan and radioligand

  • Experimental
    Part B1

    In Part B1, eligible participants who completed the first PET scan at the screening visit and/or Part A will return to the trial site for blood sampling for FAP concentration analysis and the second PET examination on Day 1 (Visit 3) using the radioligand \[68Ga\]Ga-FAPI-46. At Visit 4, on Day 7 (±2 days), participants will receive a single oral dose of AZD2389. After AZD2389 administration, the third PET examination will be performed at the PET Centre followed by blood sampling for PK analysis and FAP activity, after which the participants will return to the trial site for further follow-up and safety monitoring. The participants will then be discharged from the trial site. Two follow up visits will occur after administration of AZD2389. Visit 5 (7 days \[±2 days\]) and Visit 6 (30 days\[+7 days\]) will monitor for safety and follow-up of AEs.

    Drug: AZD2389 · Diagnostic Test: PET scan and radioligand

  • Experimental
    Part B2

    In Part B2, eligible participants who completed the first PET scan at the screening visit and/or Part A will return to the trial site for blood sampling for FAP concentration analysis and the second PET examination on Day 1 (Visit 3) using the radioligand \[68Ga\]Ga-FAPI-46. At Visit 4, on Day 7 (±2 days), participants will receive a single oral dose of AZD2389. After AZD2389 administration, the third PET examination will be performed at the PET Centre followed by blood sampling for PK analysis and FAP activity, after which the participants will return to the trial site for further follow-up and safety monitoring. The participants will then be discharged from the trial site. Two follow up visits will occur after administration of AZD2389. Visit 5 (7 days \[±2 days\]) and Visit 6 (30 days\[+7 days\]) will monitor for safety and follow-up of AEs.

    Drug: AZD2389 · Diagnostic Test: PET scan and radioligand

  • Experimental
    Part B3

    In Part B3, eligible participants who completed the first PET scan at the screening visit and/or Part A will return to the trial site for blood sampling for FAP concentration analysis and the second PET examination on Day 1 (Visit 3) using the radioligand \[68Ga\]Ga-FAPI-46. At Visit 4, on Day 7 (±2 days), participants will receive a single oral dose of AZD2389. After AZD2389 administration, the third PET examination will be performed at the PET Centre followed by blood sampling for PK analysis and FAP activity, after which the participants will return to the trial site for further follow-up and safety monitoring. The participants will then be discharged from the trial site. Two follow up visits will occur after administration of AZD2389. Visit 5 (7 days \[±2 days\]) and Visit 6 (30 days\[+7 days\]) will monitor for safety and follow-up of AEs.

    Drug: AZD2389 · Diagnostic Test: PET scan and radioligand

  • Experimental
    Part C

    In Part C (optional), participants attend the trial site during Visit 1 (screening, Day-35 to Day-14) to undergo an eligibility check. At Visit 2, the first PET examination with radioligand will be performed at least 5 days before IMP administration. At Visit 3 (Day 1), participants receive a single dose AZD2389, then undergo a second PET examination using the radioligand on Day 2, along with blood sampling for PK analysis and FAP activity. At Visit 4 (Day 8 ±2 days), participants will be admitted to the trial site for a second single dose, then undergo a third PET examination using the radioligand on Day 9, along with blood sampling. At Visit 5 (7 days ±2 days after the PET examination on Visit 4) and Visit 6 (30 days \[+7 days\]) after the drug administration on Visit 4), follow-up visits at the trial site take place for safety monitoring and follow-up of any AEs.

    Drug: AZD2389 · Diagnostic Test: PET scan and radioligand

Interventions

  • Doses of AZD2389 will be administrated orally

  • Diagnostic testPET scan and radioligand

    PET scan and radioligand

    Also known as: The participants will perform the PET examination at the PET Centre using the radioligand [68Ga]Ga-FAPI-46.

06

What researchers measure

Primary outcomes

  1. Occupancy, %: percent change from baseline in uptake of FAP PET radioligand [68Ga]Ga-FAPI-46 in the liver after a single dose of AZD2389.

    To examine target FAP occupancy in the liver by AZD2389 as measured with \[68Ga\]Ga-FAPI-46 PET.

    Time frame: PART B: Day 7(+/-2 days); PART C: Day 2 and Day 8 (+/-2 days)

Secondary outcomes

  1. Plasma concentrations of AZD2389.

    To evaluate plasma PK of AZD2389 after single doses.

    Time frame: PART B: Day 7(+/-2 days); PART C: Day 2 and Day 8 (+/-2 days)

  2. AZD2389 PK parameters calculated by: the plasma concentration vs. time curve (AUC) from 0 to infinity (AUCinf) and maximum observed concentration (Cmax)

    Blood sampling and analysis to evaluate PK plasma of AZD2389 after single doses.

    Time frame: PART B: Day 7(+/-2 days); PART C: Day 2 and Day 8 (+/-2 days)

  3. % FAP inhibition compared to baseline in plasma.

    To evaluate the plasma target engagement of AZD2389 by assessment of plasma FAP inhibition following single oral dosing.

    Time frame: PART B: Day 7(+/-2 days); PART C: Day 2 and Day 8 (+/-2 days)

  4. % aTRV (for radioligand uptake).

    To quantify test-retest reproducibility of radioligand \[68Ga\]Ga-FAPI-46 uptake in the liver.

    Time frame: PART B: Day 7(+/-2 days); PART C: Day 2 and Day 8 (+/-2 days)

  5. ICC (for radioligand uptake).

    To quantify test-retest reproducibility of radioligand \[68Ga\]Ga-FAPI-46 uptake in the liver.

    Time frame: PART B: Day 7(+/-2 days); PART C: Day 2 and Day 8 (+/-2 days)

  6. Maximum possible target occupancy (Occmax).

    A theoretical relationship between average concentration of AZD2389 in plasma during the PET examination and radioligand binding will be assumed to calculate maximum target occupancy, if possible, by curve fitting.

    Time frame: PART B: Day 7(+/-2 days); PART C: Day 2 and Day 8 (+/-2 days)

  7. The IC50 confidence interval

    A theoretical relationship between average concentration of AZD2389 in plasma during the PET examination and radioligand binding will be assumed to calculate the confidence interval associated with the IC50.

    Time frame: PART B: Day 7(+/-2 days); PART C: Day 2 and Day 8 (+/-2 days)

07

Study locations

1 site
  • Research Site
    Stockholm, 17176, Sweden
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jul 2026, 13 months.

Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
Jul 17, 2025
StartActual
May 26, 2025
Primary completionActual
Jul 2, 2026
CompletionActual
Jul 2, 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07069725
Lead sponsor
AstraZeneca
Collaborators
CTC Clinical Trial Consultants AB, Karolinska Institutet
Responsible party
Sponsor
First posted
Jul 17, 2025
Start date
May 26, 2025
Primary completion
Jul 2, 2026
Completion
Jul 2, 2026
Last update
Jul 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD2389

Start the discussion